التفاصيل البيبلوغرافية
| العنوان: |
Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma. |
| المؤلفون: |
Cañas, José A.1,2 (AUTHOR) JSastre@fjd.es, Valverde-Monge, Marcela3 (AUTHOR) marcela.valverde@quironsalud.es, Rodrigo-Muñoz, José M.1,2 (AUTHOR) jose.rodrigom@quironsalud.es, Sastre, Beatriz1,2 (AUTHOR) bssastre@fjd.es, Gil-Martínez, Marta1 (AUTHOR) marta.gilm@quironsalud.es, García-Latorre, Raquel1 (AUTHOR) raquel.garcial@quironsalud.es, Rial, Manuel J.3 (AUTHOR) manuterial@gmail.com, Gómez-Cardeñosa, Aida3 (AUTHOR) aida.gomez@fjd.es, Fernández-Nieto, Mar3 (AUTHOR) MMFernandez@fjd.es, Pinillos-Robles, Erwin J.4 (AUTHOR) erwin.pinillos@quironsalud.es, Rodríguez-Nieto, María J.4 (AUTHOR) MJRodriguezN@fjd.es, González-Mangado, Nicolás4 (AUTHOR) NGonzalez@fjd.es, Sastre, Joaquín2,3 (AUTHOR), del Pozo, Victoria1,2 (AUTHOR) vpozo@fjd.es |
| المصدر: |
Journal of Personalized Medicine. Feb2021, Vol. 11 Issue 2, p76. 1p. |
| مصطلحات موضوعية: |
*EOSINOPHILIA, *MICRORNA, *ASTHMA, *MONOCLONAL antibodies, *ASTHMATICS, *EOSINOPHILS |
| مستخلص: |
Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative PCR (qPCR). Patients showed a clinical improvement after benralizumab administration. Additionally, deregulation of miR-1246, miR-5100 and miR-338-3p was observed in severe asthmatic patients after eight weeks of therapy, and a correlation was found between miR-1246 and eosinophil counts, including a number of exacerbations per year in these severe asthmatics. In silico pathway analysis revealed that these three miRNAs are regulators of the MAPK signaling pathway, regulating target genes implicated in asthma such as NFKB2, NFATC3, DUSP1, DUSP2, DUSP5 and DUSP16. In this study, we observed an altered expression of miR-1246, miR-5100 and miR-338-3p after eight weeks of benralizumab administration, which could be used as early response markers. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder